<DOC>
	<DOCNO>NCT02737722</DOCNO>
	<brief_summary>Phase I/IIa , five cohort ascend dose two dose arm per cohort , study Type I II diabetes mellitus subject chronic infect diabetic ulcer define DUSS score 0 3 DFI wind score 1 3 .</brief_summary>
	<brief_title>Topically Applied Bisphosphocin Nu-3 Infected Diabetic Ulcers Subjects With Type I II Diabetes Mellitus</brief_title>
	<detailed_description>The study design run cohort series completion first cohort initiate next dosing level . At study visit ulcer visually examine change photograph use Aranz Medical Silhouette™ system calculate area depth ulcer . In Arm 1 , eligible subject treat single application Nu-3 placebo 4 1 ratio judge initial safety Nu-3 brief one ( 1 ) hour interval 24-hr interval post application . Bisphosphocin Nu-3 apply topically chronic infected ulcer , cover non-abrasive bandage follow initial observation period . The subject release verbal instruction leave bandage wound return follow visit within 24h ± 2h . At follow visit , bandage remove , ulcer visually examine subject clear MAD Arm 2 base recommendation PI absence SAEs . In Arm 2 , eligible subject approve PI Visit 2 examination instruct proper application bisphosphocin Nu-3 . The subject observe apply first dose clinic ensure compliance . Subjects give 7 day supply send home continue treatment . Visit 4 early case adverse event , subject return clinic examination , include visual examination ulcer , vital sign , adverse event , photo documentation , collection sample microbiology concomitant medication use . A final follow visit schedule +7 day last dose study medication ( Day 15 ) complete examination describe .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>1 . Men woman age 18 85 . 2 . Voluntary write consent , give performance clinical investigationrelated procedure part standard medical care , understand consent may withdraw time without prejudice future medical care . 3 . Nonhospitalized ambulatory subject suffer Diabetes mellitus , Type I II 4 . Diabetic foot ulcer ( ) DUSS Score 0 3 5 . Ulcerated area ( ) two ( 2 ) ulcer 0.5 6 cm2 6 . Any female child bear age must consent use medically acceptable birth control duration study 7 . Female subject must meet least one follow additional criterion : 1 . Surgically sterile bilateral tubal ligation hysterectomy . 2 . Postmenopausal least one year . 3 . If childbearing potential , practice acceptable method birth control duration clinical investigation judge Investigator , condom , foam , jelly , diaphragm , intrauterine device abstinence . 8 . Subjects willing undergo preand postclinical investigation blood collection , physical exam laboratory investigation . 1 . A DUSS Score 3 . 2 . DUSS Probing Bone = `` Yes '' 3 . An ulcer area ( ) great 6 cm2 two ( 2 ) ulcer 4 . Any subject receive systemic topical antibiotic within last seven ( 7 ) day 5 . Any subject topical antimicrobial treatment infect diabetic foot ulcer whose ulcer respond treatment 6 . Any subject would unable follow protocol procedure , safely monitor infection status home , return schedule visit 7 . Positive pregnancy test Screening Visit 2 8 . Active infection demonstrate temperature &gt; 37.5 oC clinical feature active infection . 9 . Known immunosuppression take immunosuppressive agent include systemic steroid . 10 . History severe comorbidity expect patient survival ≤ 6 month . 11 . Pregnancy lactation 12 . Intake investigational drug within 28 day prior enrollment . 13 . History concurrent condition , Investigator 's opinion , would jeopardize safety subject compliance protocol . 14 . Likely inability comply protocol cooperate fully investigator site personnel . 15 . Unwillingness language barrier preclude adequate understanding trial procedure cooperation trial site personnel . 16 . Known suspect active abuse alcohol , narcotic nonprescription drug . 17 . Other plan surgical procedure within 30 day prior 30 day postindex procedure . 18 . Prior enrollment clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>